綠茶萃取 Green Tea Extract × 癌症預防

結論:主流反證據

The evidence base for green tea extract preventing cancer is dominated by observational cohort and case-control studies that are inconsistent and prone to confounding.

D 🔴 D 反證據 主流反證據 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 🇹🇼 台灣在地警示

The evidence base for green tea extract preventing cancer is dominated by observational cohort and case-control studies that are inconsistent and prone to confounding. The strongest synthesis, the 2020 Cochrane review of 142 studies and over 1.1 million participants, found only limited evidence and a non-significant overall cancer incidence RR of 0.83 (95% CI 0.65-1.07) with mortality RR 0.99. The largest dedicated RCT, the Minnesota Green Tea Trial (932 women, 843 mg EGCG/day for 12 months), was null on its primary breast cancer risk biomarker. A 2025 meta-analysis reported modest protective RRs (green tea 0.91, EGCG 0.72) but the authors themselves cite high heterogeneity and call for validation by higher-quality studies, and both the American Cancer Society and the American Institute for Cancer Research explicitly characterize green tea cancer prevention as unproven and inconclusive. There is a biologically plausible mechanistic signal and weak suggestive associations, but no RCT proof; grade C (some signal, inconsistent, no proof) is the honest ceiling and overgrading the observational data to A or B would be unjustified.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.48
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
D · 主流反證據
信心度
79%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧/統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
L5 臨床機構權威立場
0.55
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.485
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (2 negative > 0 positive),下層 RCT 不能推翻
  4. apply_hec_override — HEC-1 高階證據 negative — 強制由 C 改為 D
  5. tier_strict_requirement_check — Tier 條件達標,未降階
  6. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  7. decide_status — 依 tier + dispute 結果決定 status

Green tea (Camellia sinensis) for the prevention of cancer
PMID: 32118296 2020 Cochrane SR n = 1,101,795
結論:142 completed studies (11 experimental RCTs with 1,795 participants; 131 non-experimental studies with >1.1 million participants). Overall cancer incidence RR 0.83 (95% CI 0.65 to 1.07, low-certainty, not significant); cancer-related mortality RR 0.99 (95% CI 0.91 to 1.07, low-certainty). Experimental prostate cancer RR 0.50 (95% CI 0.18 to 1.36, NS). Authors conclude experimental and non-experimental studies yielded inconsistent results providing only limited evidence for any beneficial effect; high green tea intake showed several adverse effects.
🟢 高品質 學術資助 效應量:Overall cancer RR 0.83 (95% CI 0.65-1.07, NS); mortality RR 0.99 (95% CI 0.91-1.07, NS)
前往 PubMed
Green Tea and Epigallocatechin Gallate (EGCG) for Cancer Prevention: A Systematic Review and Meta-Analysis
PMID: 40832777 2025 統合分析
結論:Pooled 43 studies. Green tea RR 0.91 (95% CI 0.86-0.96); EGCG RR 0.72 (95% CI 0.54-0.97). Site-specific: prostate RR 0.43 (95% CI 0.22-0.83), oral RR 0.44 (95% CI 0.01-0.87), gallbladder RR 0.72 (95% CI 0.51-0.94), hematological RR 0.72 (95% CI 0.49-0.95). Authors state findings still need validation by higher-quality studies given heterogeneity.
效應量:Green tea RR 0.91; EGCG RR 0.72
前往 PubMed
A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer (Minnesota Green Tea Trial)
PMID: 28904061 2017 RCT (double-blind) n = 932
結論:Green tea extract supplementation for 12 months did not significantly change percent or absolute mammographic density in the overall postmenopausal cohort. A subgroup of women aged 50-55 showed a 4.40% reduction in PMD vs a 1.02% increase on placebo (p=0.05), but the primary outcome was null.
🟢 高品質 政府資助 效應量:Overall PMD change not significant; younger subgroup exploratory only
前往 PubMed
Green tea and the risk of prostate cancer: A systematic review and meta-analysis
PMID: 28353571 2017 統合分析
結論:Highest vs lowest green tea intake showed no statistically significant reduction in prostate cancer risk. A dose-response trend appeared only above 7 cups/day (p=0.08). Green tea catechin supplements showed RR 0.38 (p=0.02) in the small RCT subset, but authors state additional investigations are needed to validate the findings.
效應量:High vs low intake NS; catechins RR 0.38 (p=0.02, small RCT subset)
前往 PubMed

L4a US FDA
謹慎
Oil-soluble green tea extract (green tea catechin palmitate) is considered Generally Recognized as Safe (GRAS) based on scientific procedures as an antioxidant in food 來源↗
L4b EU EFSA
反對
L4c UK NHS
謹慎
The COT concluded that there are no new data to suggest that EFSA's conclusion, that 800 mg/day EGCG was probably safe, is inappropriate. Although no new studies identified any effects of EGCG in humans at doses below 800 mg/day, the possibility cannot be excluded that a few individuals could still experience adverse effects below this dose due to an idiosyncratic reaction. 來源↗
L4d TW TFDA / 衛福部
中性
建議成人每人每天攝取兒茶素EGCG上限為800毫克,不應過量;一般沖泡綠茶飲用的民眾不必太過擔心兒茶素傷肝問題。 來源↗
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
中性
L5d Harvard Health
中性
L5e Specialty Society (condition-mapped)
中性

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 極高
📍立場總覽

台灣社群幾乎沒有『把綠茶萃取膠囊當作防癌保健品在吃』的真實實測心得;PTT/Dcard 的癌症相關討論多集中在化療後營養補充與食慾,而非綠茶萃取防癌。真正在社群與媒體被反覆轉貼的訊號是『綠茶膠囊/兒茶素傷肝』案例(男性服綠茶膠囊致肝功能受損),以及醫師澄清『喝茶 OK、但濃縮萃取物高劑量 EGCG 才是肝毒性風險』。防癌效果的論述多來自業配導向的保健品電商與直銷頁面(悠活原力、NU SKIN、formulawave、iHerb 聯盟),grassroots 真實心得稀少,stance 偏 cautious 而非 supportive。

💬社群實感

無共識(社群幾乎無『服綠茶萃取防癌』的實測心得,討論多偏向減重/抗氧化與肝毒性警示,而非防癌療效)

破解迷思 社群最常見的 4 個誤解
事實以為『綠茶萃取膠囊能防癌/抗癌』有實證療效(實為保健品行銷誇大宣稱,人體證據不足,僅流行病學與細胞研究觀察)
事實誤以為『萃取濃縮膠囊比喝茶更防癌更有效』(實際上高劑量濃縮 EGCG 才是肝毒性風險來源,喝原型綠茶反而較安全)
事實把『日本研究每天 4 杯綠茶降癌風險 40%』直接等同於『吃綠茶萃取膠囊就能防癌』(飲茶與高劑量萃取物不可混為一談)
事實誤以為綠茶萃取物天然無害、可長期大量補充(忽略兒茶素肝毒性與咖啡因問題)
🩹 社群通報的副作用
  • 肝功能受損/肝指數異常(媒體與社群轉貼之綠茶膠囊致急性肝炎案例)
  • 空腹服用腸胃不適、噁心
  • 含咖啡因者出現心悸、失眠
  • 抑制鐵質吸收(缺鐵者需留意)
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • NU SKIN 綠茶菁萃膠囊(直銷)
  • NOW Foods EGCg Green Tea Extract(iHerb 常見)
  • BHK's 綠茶兒茶素
  • 悠活原力 綠茶兒茶素相關產品

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

綠恩兒茶素(綠茶萃取錠)獲衛福部健康食品認證,編號為衛署健食字第A00179號

代表來源 ↗
L10b · TFDA 法定身份 官方認定

臺灣針對經萃取出綠茶兒茶素EGCG製成的保健膠囊都有規範,必須符合每日上限300毫克的限制才可以販售

來源 ↗

  • 戒菸與避免菸品暴露
  • 維持健康體重、規律運動與健康飲食
  • 疫苗接種(HPV、B 型肝炎)與癌症篩檢
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 4 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v24 engine_version: v1.0 claim_id: CLM-COND-cancer-prevention-INT-green-tea-extract-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-cancer-prevention-INT-green-tea-extract-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "綠茶萃取能改善癌症預防",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 1,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🔴 D 反證據"
  }
}